Cargando…

Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy

We evaluated the reproducibility and predictive value of texture parameters and existing parameters of (18)F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Kazuya, Takanami, Kentaro, Shirata, Yuko, Yamamoto, Takaya, Takahashi, Noriyoshi, Ito, Kengo, Takase, Kei, Jingu, Keiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710655/
https://www.ncbi.nlm.nih.gov/pubmed/29036692
http://dx.doi.org/10.1093/jrr/rrx050
_version_ 1783282942636720128
author Takeda, Kazuya
Takanami, Kentaro
Shirata, Yuko
Yamamoto, Takaya
Takahashi, Noriyoshi
Ito, Kengo
Takase, Kei
Jingu, Keiichi
author_facet Takeda, Kazuya
Takanami, Kentaro
Shirata, Yuko
Yamamoto, Takaya
Takahashi, Noriyoshi
Ito, Kengo
Takase, Kei
Jingu, Keiichi
author_sort Takeda, Kazuya
collection PubMed
description We evaluated the reproducibility and predictive value of texture parameters and existing parameters of (18)F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospectively analyzed. All of the patients underwent an (18)F-FDG PET/CT scan before treatment and were treated with SBRT. Each tumor was delineated using PET Edge (MIM Software Inc., Cleveland, OH), and texture parameters were calculated using open-source code CGITA. From (18)F-FDG PET/CT images, three conventional parameters, including maximum standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), and four texture parameters, including entropy and dissimilarity (derived from a co-occurrence matrix) and high-intensity large-area emphasis (HILAE) and zone percentage (derived from a size-zone matrix) were analyzed. Reproducibility was evaluated using two independent delineations conducted by two observers. The ability to predict local control (LC), progression-free survival (PFS) and overall survival (OS) was tested for each parameter. All of the seven parameters except zone percentage showed good reproducibility, with intraclass correlation coefficient values >0.8. In univariate analysis, only HILAE was a significant predictor for LC. Histology, dose fractionation, and maximum SUV were associated with PFS, and histology and dose fractionation were associated with OS. We showed that texture parameters derived from (18)F-FDG PET/CT were reproducible and potentially beneficial for predicting LC in Stage I lung cancer patients treated with SBRT.
format Online
Article
Text
id pubmed-5710655
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-57106552017-12-07 Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy Takeda, Kazuya Takanami, Kentaro Shirata, Yuko Yamamoto, Takaya Takahashi, Noriyoshi Ito, Kengo Takase, Kei Jingu, Keiichi J Radiat Res Oncology We evaluated the reproducibility and predictive value of texture parameters and existing parameters of (18)F-FDG PET/CT images in Stage I non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiotherapy (SBRT). Twenty-six patients with Stage I NSCLC (T1-2N0M0) were retrospectively analyzed. All of the patients underwent an (18)F-FDG PET/CT scan before treatment and were treated with SBRT. Each tumor was delineated using PET Edge (MIM Software Inc., Cleveland, OH), and texture parameters were calculated using open-source code CGITA. From (18)F-FDG PET/CT images, three conventional parameters, including maximum standardized uptake value (SUV), metabolic tumor volume (MTV) and total lesion glycolysis (TLG), and four texture parameters, including entropy and dissimilarity (derived from a co-occurrence matrix) and high-intensity large-area emphasis (HILAE) and zone percentage (derived from a size-zone matrix) were analyzed. Reproducibility was evaluated using two independent delineations conducted by two observers. The ability to predict local control (LC), progression-free survival (PFS) and overall survival (OS) was tested for each parameter. All of the seven parameters except zone percentage showed good reproducibility, with intraclass correlation coefficient values >0.8. In univariate analysis, only HILAE was a significant predictor for LC. Histology, dose fractionation, and maximum SUV were associated with PFS, and histology and dose fractionation were associated with OS. We showed that texture parameters derived from (18)F-FDG PET/CT were reproducible and potentially beneficial for predicting LC in Stage I lung cancer patients treated with SBRT. Oxford University Press 2017-11 2017-09-21 /pmc/articles/PMC5710655/ /pubmed/29036692 http://dx.doi.org/10.1093/jrr/rrx050 Text en © The Author 2017. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oncology
Takeda, Kazuya
Takanami, Kentaro
Shirata, Yuko
Yamamoto, Takaya
Takahashi, Noriyoshi
Ito, Kengo
Takase, Kei
Jingu, Keiichi
Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title_full Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title_fullStr Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title_full_unstemmed Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title_short Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
title_sort clinical utility of texture analysis of 18f-fdg pet/ct in patients with stage i lung cancer treated with stereotactic body radiotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710655/
https://www.ncbi.nlm.nih.gov/pubmed/29036692
http://dx.doi.org/10.1093/jrr/rrx050
work_keys_str_mv AT takedakazuya clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT takanamikentaro clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT shiratayuko clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT yamamototakaya clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT takahashinoriyoshi clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT itokengo clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT takasekei clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy
AT jingukeiichi clinicalutilityoftextureanalysisof18ffdgpetctinpatientswithstageilungcancertreatedwithstereotacticbodyradiotherapy